Biopharmaceuticals Market Forecasts to 2030 - Global Analysis By Product Type, Application and By Geography

According to Stratistics MRC, the Global Biopharmaceuticals Market is accounted for $1047.45 million in 2023 and is expected to reach $2686.05 million by 2030 growing at a CAGR of 14.4% during the forecast period. Biopharmaceuticals, also referred to as biologic drugs or biologics, are pharmaceuticals made from living things like cells, organisms, or proteins. These medications are produced using biotechnology techniques and are essential to contemporary healthcare. Moreover, biopharmaceuticals have made it possible to develop personalized medicine strategies. These medications have the potential to target particular molecular aspects of a patient's illness, enabling the development of personalized treatment plans based on the patient's particular genetic profile or disease subtype.

According to the International Agency for Research on Cancer, in the year 2020, around 19.3 million new cases of cancer were diagnosed and around 10 million cancer deaths were recorded. The cancer cases are estimated to grow by 47% from 2020 to 2040.

Market Dynamics:

Driver:

Expanding scientific advances

Biopharmaceutical R&D is being transformed by ongoing scientific advances in structural biology, gene editing, and high-throughput screening methods. Drug design is aided by the understanding of bimolecular structures provided by cryo-electron microscopy and cutting-edge imaging technologies. Massive datasets are analyzed using artificial intelligence and machine learning to make predictions about drug discovery. Additionally, gene therapies and gene-edited cell therapies have been made possible by advances in synthetic biology, such as CRISPR-Cas9, expanding the range of biopharmaceuticals.

Restraint:

Excess development costs

Financial investments in research, preclinical studies, and challenging clinical trials are significant in the development of biopharmaceuticals. In addition to these basic costs, biopharmaceutical businesses also have to spend money on specialized infrastructure, such as state-of-the-art lab tools and specialized manufacturing facilities, all of which drive up development costs. Furthermore, the lengthy and resource-intensive nature of biopharmaceutical development, where costs frequently exceed billions of dollars for a single drug candidate, further exacerbates financial difficulties.

Opportunity:

Increasing clinical trials and personalized medicine

Precision medicine, which tailors treatments to a person's genetic profile and particular disease characteristics, is being made possible by developments in genomics and molecular diagnostics. With this strategy, treatment effectiveness is improved, side effects are minimized, and patient outcomes are optimized. Moreover, oncology is a field where personalized medicine holds particular promise because biomarker-driven therapies are increasing survival and response rates.

Threat:

Challenges to intellectual property (IP)

A complex web of patents, trade secrets, and patent thickets must be negotiated by businesses due to the global nature of the biopharmaceutical market, which presents additional IP challenges. Additionally, the emergence of biosimilars brings with it new legal complexities, such as patent disputes and patent thicket strategies, where multiple patents are used to cover a single product and provide for extended market exclusivity.

COVID-19 Impact:

The COVID-19 pandemic affected the biopharmaceutical industry significantly and in a variety of ways. In addition to delaying clinical trials, disrupting global supply chains, and refocusing resources on pandemic-related activities, the urgent need for vaccines and treatments accelerated research and development efforts. Moreover, the pandemic highlighted the significance of vaccine development, antiviral therapies, and biopharmaceutical innovation, leading to increased investments in these fields. It also exposed weaknesses in supply chains, forcing businesses to reconsider their distribution and manufacturing plans.

The Vaccines segment is expected to be the largest during the forecast period

The vaccines segment typically holds the largest share of the market. A wide range of infectious diseases are prevented by vaccines, which are essential to public health. They have become more well-known for both current threats like COVID-19 and emerging ones like influenza and hepatitis. The global demand for vaccines has increased dramatically as a result of the COVID-19 pandemic in particular. However, the vaccine market is still essential to the expansion of the biopharmaceutical industry and efforts to improve public health due to ongoing research and development activities, including the creation of new vaccine platforms like mRNA vaccines.

The Oncology segment is expected to have the highest CAGR during the forecast period

The biopharmaceutical market's highest CAGR is anticipated in the oncology segment. This is mainly because of a number of things, such as the rising incidence of cancer globally, developments in targeted and immunotherapeutic therapies, and ongoing work on precision medicine methods. Moreover, the oncology market has experienced significant growth as a result of the creation of novel biopharmaceuticals for various cancer types as well as the potential for combination therapies and biomarker-driven treatments.

Region with largest share:

The global biopharmaceutical market typically holds the largest share in the North American region, in particular the United States. A strong pharmaceutical industry, significant R&D expenditures, a developed healthcare system, a sizable patient base, and a supportive regulatory environment for the development and commercialization of biopharmaceuticals were all cited as contributing factors to this dominance. Additionally, its sizeable market share was influenced by the fact that North America is home to a large number of biopharmaceutical businesses, academic research centers, and biotechnology hubs.

Region with highest CAGR:

The biopharmaceutical market was growing at the highest CAGR in the Asia-Pacific region. A rising middle-class population, rising healthcare costs, growing pharmaceutical manufacturing capacity, and rising demand for cutting-edge treatments are just a few of the reasons for this industry's rapid growth. Due to their investments in R&D, clinical trials, and the production of biologic drugs and vaccines, nations like China and India in particular were emerging as major players in the biopharmaceutical industry. Moreover, the region's rapid growth was also aided by supportive government policies and partnerships with major pharmaceutical corporations.

Key players in the market:

Some of the key players in Biopharmaceuticals market include: Merck & Co., Inc. , Novartis AG, Abbott Laboratories., Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Biogen Inc. , AbbVie Inc., Pfizer Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Sanofi, Bayer AG, Allergan plc , Johnson & Johnson and Amgen Inc.

Key Developments:

In October 2023, Sanofi has reached an agreement to develop and commercialize an experimental vaccine candidate for extra intestinal pathogenic E. coli developed by Janssen Pharmaceuticals. Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m upfront, followed by development and commercial milestones. Both parties will co-fund current and future research and development costs. Extra intestinal pathogenic E. coli is a common gram-negative bacteria pathogen in humans and a leading cause of sepsis, particularly in older adults.

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's Library of Libraries, a collection of synthetic antibody libraries that harnesses innovative structural and develops ability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of antibody discovery programs across indications and focus areas.

In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical. Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered:

• Monoclonal Antibodies
• Interferon
• Insulin
• Growth and Coagulation Factor
• Vaccines
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Synthetic Immunomodulators
• Recombinant Hormones
• Recombinant Enzymes
• Cell and Gene Therapies
• Synthetic Immunomodulators
• Other Product Types

Applications Covered:

• Oncology
• Blood disorder
• Metabolic disease
• Infectious disease
• Cardiovascular disease
• Neurological disease
• Immunology
• Autoimmune Disorders
• Hormonal Disorders
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances